- Report
- April 2025
- 200 Pages
Global
From €4029EUR$4,490USD£3,467GBP
- Report
- May 2024
- 138 Pages
Global
From €5831EUR$6,499USD£5,019GBP
- Report
- May 2024
- 140 Pages
Global
From €5831EUR$6,499USD£5,019GBP
- Report
- May 2024
- 131 Pages
Global
From €5831EUR$6,499USD£5,019GBP
- Report
- May 2024
- 133 Pages
Global
From €5831EUR$6,499USD£5,019GBP
- Drug Pipelines
- April 2024
- 80 Pages
Global
From €1346EUR$1,500USD£1,158GBP
- Report
- October 2023
- 175 Pages
Global
From €4038EUR$4,500USD£3,475GBP
- Drug Pipelines
- January 2022
- 30 Pages
Global
From €449EUR$500USD£386GBP
Humatrope is a brand of recombinant human growth hormone (rHGH) used to treat endocrine and metabolic disorders. It is used to treat growth failure in children and adults due to inadequate secretion of endogenous growth hormone, and to treat short stature associated with Turner Syndrome, Prader-Willi Syndrome, and chronic renal insufficiency. It is also used to treat adults with growth hormone deficiency.
Humatrope is a biopharmaceutical product that is administered via subcutaneous injection. It is available in a variety of dosage strengths and is approved for use in the United States, Europe, and other countries.
The Humatrope market is a competitive one, with several companies offering their own versions of the product. Companies in the market include Eli Lilly, Novo Nordisk, Pfizer, and Sandoz. Show Less Read more